lilly tirzepatide lawsuit Weight loss drug lawsuit: Mounjaro maker files suit over compounded products US judge denies injunction, restricting

Afamelanotide (brand name Scenesse) received FDA approval in 2019 for adults with erythropoietic protoporphyria, a rare disorder that causes severe pain from light exposure (Scenesse, Drugs.com)

However, as discussed in a later comment summary, several commenters indicated that there are scenarios in which a hospital does not have access to EDI 835 ERA transaction data

In fact, tirzepatide was originally approved as Mounjaro for diabetes management before receiving approval as Zepbound for weight loss

Secure Storage: Keep the product in a safe place that is out of reach of children and away from unauthorized access